Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

AURA - Aura Biosciences, Inc.


IEX Last Trade
8.235
0.015   0.182%

Share volume: 0
Last Updated: Thu 26 Dec 2024 03:27:59 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 3.82%

PREVIOUS CLOSE
CHG
CHG%

$8.22
0.01
0.18%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
0.37%
1 Month
-7.32%
3 Months
-4.86%
6 Months
20.85%
1 Year
-5.62%
2 Year
-24.36%
Key data
Stock price
$8.24
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$7.08 - $12.38
52 WEEK CHANGE
-$9.46
MARKET CAP 
394.369 M
YIELD 
N/A
SHARES OUTSTANDING 
49.606 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
1.92
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$255,706
AVERAGE 30 VOLUME 
$202,709
Company detail
CEO: Elisabet de los Pinos
Region: US
Website: aurabiosciences.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Aura Biosciences, Inc. develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

Recent news